Overview

Local Injection and Systemic Therapy in the Treatment of NSCLC.

Status:
NOT_YET_RECRUITING
Trial end date:
2026-10-30
Target enrollment:
Participant gender:
Summary
This study is a prospective, exploratory Phase II clinical study aimed at evaluating the safety and efficacy of Envafolimab and recombinant human endostatin and Recombinant Human Adenovirus Type 5 Intratumor local injection combined with systemic therapy in patients with locally advanced or advanced non-small cell lung cancer(NSCLC).
Phase:
PHASE2
Details
Lead Sponsor:
Henan Cancer Hospital
Treatments:
endostar protein
Endostatins
envafolimab